Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 6/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25525861 | 0.98 | MAPT (0.42) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL25227369 | 0.97 | CHKA (0.42) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL25241722 | 0.88 | MEN1 (0.41) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25525855 | 0.87 | MEN1 (0.42) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL25241723 | 0.85 | MEN1 (0.41) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL25207278 | 0.85 | TP53 (0.38) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL25208106 | 0.84 | ESR1 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25525849 | 0.83 | TP53 (0.39) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25525880 | 0.83 | ESR1 (0.32) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL25233563 | 0.82 | CHRM2 (0.32) | CHKACHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165978-A1 | Composition and A Method For Diagnosing And Treating Bacterial Infection | Hong Kong Centre for Cerebro-Cardiovascular Health Engineering Limited (HK) | 2023-06-01 | — | — | US | claimed |
| US-20230165978-A1 | Composition and A Method For Diagnosing And Treating Bacterial Infection | Hong Kong Centre for Cerebro-Cardiovascular Health Engineering Limited (HK) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165978-A1 | Composition and A Method For Diagnosing And Treating Bacterial Infection | NOD2, PYCARD, NOD1 | CHRM2 3603/4885CHRM3 3035/4885MAPT 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.